Canada Life’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.53M | Buy |
49,007
+847
| +2% | +$43.1K | ﹤0.01% | 1067 |
|
|
2025
Q4 | $2.39M | Sell |
48,160
-12,881
| -21% | -$626K | ﹤0.01% | 1095 |
|
|
2025
Q3 | $2.9M | Sell |
61,041
-895
| -1% | -$36K | ﹤0.01% | 1069 |
|
|
2025
Q2 | $1.95M | Buy |
61,936
+3,336
| +6% | +$107K | ﹤0.01% | 1205 |
|
|
2025
Q1 | $1.92M | Sell |
58,600
-6,340
| -10% | -$225K | ﹤0.01% | 1206 |
|
|
2024
Q4 | $2.35M | Sell |
64,940
-4,862
| -7% | -$171K | ﹤0.01% | 1195 |
|
|
2024
Q3 | $2.18M | Buy |
69,802
+3,286
| +5% | +$103K | ﹤0.01% | 1262 |
|
|
2024
Q2 | $1.78M | Buy |
66,516
+12,075
| +22% | +$350K | ﹤0.01% | 1333 |
|
|
2024
Q1 | $1.85M | Buy |
54,441
+11,019
| +25% | +$328K | ﹤0.01% | 1287 |
|
|
2023
Q4 | $1.25M | Sell |
43,422
-2,749
| -6% | -$72.9K | ﹤0.01% | 1434 |
|
|
2023
Q3 | $1.27M | Sell |
46,171
-1,354
| -3% | -$41.2K | ﹤0.01% | 1394 |
|
|
2023
Q2 | $1.43M | Sell |
47,525
-4,278
| -8% | -$150K | ﹤0.01% | 1361 |
|
|
2023
Q1 | $1.88M | Sell |
51,803
-3,372
| -6% | -$130K | ﹤0.01% | 1261 |
|
|
2022
Q4 | $1.97M | Sell |
55,175
-4,296
| -7% | -$149K | 0.01% | 1242 |
|
|
2022
Q3 | $2.01M | Buy |
59,471
+6,582
| +12% | +$214K | 0.01% | 1176 |
|
|
2022
Q2 | $1.53M | Buy |
52,889
+7,030
| +15% | +$201K | ﹤0.01% | 1280 |
|
|
2022
Q1 | $1.52M | Buy |
45,859
+289
| +0.6% | +$8.86K | ﹤0.01% | 1339 |
|
|
2021
Q4 | $1.33M | Buy |
45,570
+304
| +0.7% | +$9.22K | ﹤0.01% | 1407 |
|
|
2021
Q3 | $1.22M | Hold |
45,266
| – | – | ﹤0.01% | 1440 |
|
|
2021
Q2 | $1.39M | Sell |
45,266
-856
| -2% | -$26.2K | ﹤0.01% | 1356 |
|
|
2021
Q1 | $1.21M | Sell |
46,122
-5,998
| -12% | -$168K | ﹤0.01% | 1425 |
|
|
2020
Q4 | $1.31M | Sell |
52,120
-6,432
| -11% | -$138K | ﹤0.01% | 1374 |
|
|
2020
Q3 | $1.22M | Sell |
58,552
-6,216
| -10% | -$141K | ﹤0.01% | 1314 |
|
|
2020
Q2 | $1.54M | Sell |
64,768
-5,319
| -8% | -$118K | ﹤0.01% | 1212 |
|
|
2020
Q1 | $1.26M | Buy |
70,087
+6,799
| +11% | +$143K | ﹤0.01% | 1174 |
|
|
2019
Q4 | $1.49M | Buy |
+63,288
| New | +$1.54M | ﹤0.01% | 1302 |
|
|
2019
Q3 | – | Sell |
-69,919
| Closed | -$2.31M | – | 2134 |
|
|
2019
Q2 | $2.31M | Sell |
69,919
-246
| -0.4% | -$8.43K | 0.01% | 1104 |
|
|
2019
Q1 | $2.46M | Buy |
70,165
+2,000
| +3% | +$74.4K | 0.01% | 931 |
|
|
2018
Q4 | $2.09M | Buy |
68,165
+3,539
| +5% | +$152K | 0.01% | 977 |
|
|
2018
Q3 | $3.25M | Sell |
64,626
-2,217
| -3% | -$109K | 0.01% | 879 |
|
|
2018
Q2 | $4M | Hold |
66,843
| – | – | 0.01% | 790 |
|
|
2018
Q1 | $3.06M | Sell |
66,843
-140
| -0.2% | -$5.84K | 0.01% | 897 |
|
|
2017
Q4 | $2.67M | Sell |
66,983
-1,676
| -2% | -$66.2K | 0.01% | 989 |
|
|
2017
Q3 | $2.69M | Sell |
68,659
-4,155
| -6% | -$180K | 0.01% | 963 |
|
|
2017
Q2 | $3.13M | Buy |
72,814
+2,220
| +3% | +$79K | 0.01% | 873 |
|
|
2017
Q1 | $2.21M | Buy |
70,594
+5,729
| +9% | +$154K | 0.01% | 1066 |
|
|
2016
Q4 | $1.64M | Sell |
64,865
-1,559
| -2% | -$34.8K | ﹤0.01% | 1215 |
|
|
2016
Q3 | $1.64M | Buy |
66,424
+20,503
| +45% | +$464K | ﹤0.01% | 1171 |
|
|
2016
Q2 | $935K | Buy |
45,921
+40,721
| +783% | +$722K | ﹤0.01% | 1448 |
|
|
2016
Q1 | $79K | Hold |
5,200
| – | – | ﹤0.01% | 1922 |
|
|
2015
Q4 | $70K | Hold |
5,200
| – | – | ﹤0.01% | 1989 |
|
|
2015
Q3 | $73K | Buy |
+5,200
| New | +$96.7K | ﹤0.01% | 1909 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Canada Life's SUPN Position: Q1 2026 in Review
Canada Life increased its Supernus Pharmaceuticals (SUPN) stake by 1.8% in Q1 2026, buying an estimated $43.1K and bringing the position to 49,007 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1067.
Canada Life first reported a position in SUPN in Q3 2015 and has held it in 42 quarters since. The position peaked at $4M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Canada Life held 49,007 shares of Supernus Pharmaceuticals worth $2.53M as of Q1 2026.
- Canada Life bought 847 Supernus Pharmaceuticals shares in Q1 2026, an estimated $43.1K.
- Supernus Pharmaceuticals made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1067 holding.
- Canada Life first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 42 quarters since.
- Canada Life's Supernus Pharmaceuticals position peaked at $4M in Q2 2018.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.